Lipocine
LPCN • NASDAQ
Lipocine is a biotechnology company in the healthcare sector trading on NASDAQ, led by CEO Mahesh V. Patel, with a market cap of $52.2M.
CEOMahesh V. Patel
Next Earnings
Upcoming earnings announcement for Lipocine
Date
Thursday, May 7, 2026 (in a month)
Timing
Before Market Open (8:00 AM New York)
Fiscal Period
Q1 2026
EPS Estimate
-$0.52
Revenue Estimate
$175.0K
Earnings History
Past 12 earnings reports for Lipocine
| Date | Period | EPS | EPS Surprise | Revenue | Rev. Surprise | Filing |
|---|---|---|---|---|---|---|
| Mar 10, 2026 | Q4 2025 | -$0.34Est: -$0.61 | +44.3% | $1.1MEst: $109.6K | +944.7% | — |
| Nov 6, 2025 | Q3 2025 | -$0.59Est: -$0.55 | -7.3% | $114.6KEst: $182.8K | -37.3% |  10-Q |
| Aug 5, 2025 | Q2 2025 | -$0.41Est: -$0.41 | 0.0% | $622.8KEst: $537.4K | +15.9% | 10-Q |
| May 8, 2025 | Q1 2025 | -$0.35 | — | $93.9KEst: $352.0K | -73.3% | 10-Q |
| Mar 13, 2025 | Q4 2024 | $0.33Est: -$0.38 | +186.8% | $3.5MEst: $200.0K | +1645.5% | 10-K |
| Nov 7, 2024 | Q3 2024 | -$0.44Est: -$0.48 | +8.3% | -Est: $150.0K | -100.0% | 10-Q |
| Aug 8, 2024 | Q2 2024 | -$0.56Est: -$0.78 | +28.2% | $89.6KEst: $290.0K | -69.1% | 10-Q |
| May 9, 2024 | Q1 2024 | $0.66Est: -$0.68 | +197.1% | $7.6M | — | 10-Q |
| Mar 7, 2024 | Q4 2023 | -$0.42Est: -$0.47 | +10.6% | $216.2K | — | 10-K |
| Nov 8, 2023 | Q3 2023 | -$1.27Est: -$0.60 | -111.7% | -$3.1MEst: $470.0K | -764.3% | — |
| Aug 10, 2023 | Q2 2023 | -$0.68Est: -$0.64 | -6.3% | -Est: $280.0K | -100.0% | 10-Q |
| May 11, 2023 | Q1 2023 | -$0.68Est: -$0.34 | -100.0% | $55.0KEst: $780.0K | -93.0% | 10-Q |